The J. David Gladstone Institutes

Xyphos Biosciences Inc.

Eytan Herzig

Warner C Greene

Kaman C Kim

Nigel Killeen

This application relates generally to the production of modified, non-natural &#x3b1;1-&#x3b1;2 domains of NKG2D ligands with attached polypeptides having specific target-binding properties, for example, antibodies or variable fragments of antibodies, that are selectively delivered to Chimeric Antigen Receptors (CARs) comprised of modified, non-natural NKG2D receptors on engineered mammalian cells. The targeting of surface-expressed molecules includes those of virus-infected cells that can then be attacked and ablated by engineered cells of the immunity system expressing CARs cognate to the modified, non-natural &#x3b1;1-&#x3b1;2 domains of NKG2D ligands with attached polypeptides.

Growing community of inventors

South San Francisco, CA, United States of America

Eytan Herzig